Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

NCT00283803 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Exisulind
DRUG: luteinizing hormone-releasing hormone (LHRH) agonist
DRUG: Antiandrogen

Sponsor

University of Washington

Collaborators

[object Object]